Abstract

FORMULATION AND EVALUATION OS SUSTAINED RELEASE MATRIX TABLETS OF GLIBENCLAMIDE

Kanika Nayak*, A. K. Singhai, Gourav K. Saraogi, Sarvesh Sharma, M. K. Mishra

Abstract

The present work is aimed to design, develop and evaluate sustained release matrix tablets of glibenclamide capable of delivering drug at nearly constant rate, suitable for once a day administration. Glibenclamide is an oral hypoglycaemic agent, which is a drug for the treatment of patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) and given in insulin resistance condition. . The relatively small daily dose, short half life, undesirable side effects and rapid absorption from the GIT make GBD a good candidate for formulation in a sustained release dosage form. GBD was incorporated in 5 formulae containing hydroxypropylmethylcellulose (HPMC) as a matrix former in variable quantity. Microcrystalline Cellulose (MCC) was added to formulae in different amounts in order to disintegrate the tablets and magnesium stearate was added as a lubricant. Direct compression techniques was used to prepare the tablets. The physical properties were found to be satisfactory for all the formulae. Swelling behaviour of sustained release matrix tablets showed increase in % weight gain in phosphate buffer pH 7.4 due to increase in amount of hydrophilic polymer. In-vitro release study was performed by using USP type-2 dissolution apparatus. In- vitro release data showed that there is retardation of drug release with increase in amount of polymer. The drug release indicated that the release of drug predominately is a diffusion-controlled process through polymer matrix.

Keywords: Diabetes mellitus, Glibenclamide, Sustained releae, Extended release.